Table 2.
Risk category percentilea | No. of individuals | Risk estimates for PRS groups | ||
---|---|---|---|---|
Controls | Cases | OR (95% CI)b | p-value | |
≤1% | 530 | 339 | 0.52 (0.45–0.59) | 2.11 × 10−20 |
1%–10% | 4771 | 3636 | 0.62 (0.59–0.65) | 6.26 × 10−90 |
10%–25% | 7936 | 7359 | 0.75 (0.72–0.78) | 3.62 × 10−54 |
25%–75% | 26,464 | 32,743 | 1.00 (Ref) | |
75%–90% | 7940 | 13,431 | 1.37 (1.32–1.41) | 6.55 × 10−77 |
90%–99% | 4766 | 11,451 | 1.93 (1.86–2.01) | 4.13 × 10−249 |
>99% | 528 | 2576 | 3.99 (3.62–4.40) | 5.64 × 10−172 |
Note: PRS were calculated for variants from the final stepwise model with allele dosage from OncoArray and iCOGS weighted by the per-allele conditionally adjusted odds ratios from the meta-analysis
aRisk category groups were based on the percentile distribution of risk alleles in overall controls
bEstimated effect of each PRS group relative to the interquartile range (25–75%) in OncoArray and iCOGS datasets separately, and then meta-analyzed across the two studies; odds ratios were adjusted for country and 7(OncoArray)/8(iCOGS) principal components